11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 01.03.2026 Expectation: 7500 pips
Investing in silver with $86 in sight
Today at 11:08 AM 9
Brent sell
Period: 28.02.2026 Expectation: 90 pips
Brent crude selloff with $71.30 target
Today at 09:54 AM 13
Brent sell
Period: 28.02.2026 Expectation: 550 pips
Brent crude is vulnerable to steep pullback on geopolitical de-escalation
Today at 08:59 AM 13
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 28.02.2026 Expectation: 1120 pips
Temporary surge in oil prices won’t stop AUDCAD’s long-term ascent
Today at 08:17 AM 12
Period: 31.03.2026 Expectation: 900 pips
Investing in USDCAD when American GDP beats forecasts
Today at 06:04 AM 9
Brent sell
Period: 30.04.2026 Expectation: 200 pips
Selling Brent crude as it climbs to $73.0
Today at 04:23 AM 8
Go to forecasts